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Abstract. The role of paraoxonase 1 in cardiovascular disease complications in
type 2 diabetes mellitus is not fully understood. We studied paraoxonase activity
towards paraoxon in 188 non-diabetic and 140 diabetic subjects using general lin-
ear models and univariate analysis. Adjusting for age revealed a reduction in ac-
tivity towards paraoxon was associated with a significant increase in risk (p=0.023)
for cardiovascular disease complications in diabetic patients. Multivariate analy-
sis of two plasma measures of paraoxonase activity using paraoxon and diazoxon
also showed reduced paraoxonase activity towards paraoxon was associated with
a significant increase in risk (p=0.045) for cardiovascular disease complications in
diabetic patients. These analyses showed that a reduced paraoxonase activity
towards paraoxon was associated with ethnicity. Based on multivariate analysis,
subjects of Malay ethnic origin have significantly higher than expected activity
(p=0.008, compared to Indians), towards paraoxon than subjects of Chinese origin
who in turn had higher than expected paraoxonase activity (p=0.028, compared to
Indians) Indian subjects.
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INTRODUCTION
Paraoxonase 1 (PON1) is associated
with the development of atherosclerosis
(Mackness et al, 2010).  The hydrolytic ac-
tive site of PON1 has been shown to me-
diate two major anti-atherogenic func-
tions: protection of low-density lipopro-
tein (LDL) from oxidation and stimulation
of high-density lipoprotein (HDL)-medi-
ated macrophage cholesterol efflux
(Rosenblat et al, 2006). There is also increas-
ing evidence that highlights the associa-
tion between PON1 and diabetes mellitus
(DM) (Hofer et al, 2006). PON1 is physi-
cally associated with HDL. Individuals
with type 2 DM may present with low HDL
levels (Sarkar et al, 2006) or may present
with levels comparable with healthy sub-
jects (van Wijk et al, 2006; Saeed et al, 2007).
However, the HDL apoproteins may be
highly glycated in diabetics compared to
those in normoglycemic individuals
(Norata et al, 2006). Glycation of HDL ap-
pears to inhibit PON1 activity, implying
that insulin resistance is associated with
impaired PON1 activity (Hedrick et al,
2000). When PON1 becomes impaired, its
ability to impede LDL oxidation is reduced,
leading to accelerated atherosclerosis.
Hyperglycemia also induces oxidative
stress via several mechanisms resulting in
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increased reactive oxygen species (ROS)
generation (Jay et al, 2006). Although en-
dogenous ROS help to maintain homeosta-
sis, their excess over a prolonged period of
time may cause oxidative stress leading to
proatherogenic events.
Several studies have shown lower lev-
els of PON1 activity in diabetics compared
to healthy subjects (Mastorikou et al, 2006).
A post-prandial reduction in HDL-choles-
terol (HDL-C) and PON1 activity was ob-
served in type 2 diabetics who were given
fresh cream (van Wijk et al, 2006). In
healthy individuals the consumption of
similar fat results in increased PON1 ac-
tivity (Sutherland et al, 1999). These find-
ings suggest decreased protection of lipo-
proteins against oxidation in diabetics.
However, the mechanism leading to de-
creased post-prandial PON1 activity in
diabetics is not fully known. A negative
correlation has also been found between
PON1 activity and oxidized LDL concen-
tration in healthy subjects, but not in type
2 diabetics (Mastorikou et al, 2006). Poor
glycemic control in diabetics has been cor-
related with high glycation and low PON1
activity, leading to a decreased ability to
metabolize oxidized LDL.
The present cross-sectional study was
carried out based on the hypothesis HDL-
associated PON1 decreases accumulation
of oxidized LDL in vitro, contributing to
the attenuation of atherosclerosis in type
2 DM. This study evaluates PON1 activ-
ity as a parameter for prognosis of cardio-
vascular diseases (CVD) in type 2 diabe-
tes.
MATERIALS AND METHODS
Subjects
A group of subjects comprising out-
patients who attended the Diabetic Clinic
of the University of Malaya Medical Cen-
tre, Kuala Lumpur, Malaysia and healthy
volunteers residing in Selangor and Kuala
Lumpur, were selected. The demographic
characteristics of these subjects were re-
corded.
This study was approved by the Medi-
cal Ethics Committee and informed con-
sent was obtained from each subject in-
cluded in the study.
Blood sampling
Venous blood was obtained by a
trained phlebotomist under sterile condi-
tions from subjects. Blood was collected in
appropriate vacutainers for glucose, lipid
profile, and enzyme activity. The plasma
for enzyme activity was collected after cen-
trifugation of the blood for 5 minutes at
500g within three hours of sampling.
Determination of glucose and lipid pro-
file
The measurement of glucose, total
cholesterol, triglycerides and HDL-C were
carried out using the Dimension® clinical
chemistry system (Dade Behring,
Deerfield, IL). LDL-C was calculated us-
ing the Friedewald formula. Analyses
were carried out the Clinical Diagnostic
Laboratory, University of Malaya Medical
Centre.
Determination of PON1 enzymatic acti-
vity
Paraoxonase (POase) and diazoxonase
(DZOase) activities were analyzed spectro-
photometrically. Paraoxon (1.2 M) (Sigma
Chemical, St. Louis, MO) and diazoxon
(1.0 M) (Chemservice, West Chester) were
used as substrates, respectively, in a Tris
buffer (0.1 M, pH 8.5) containing 2 M NaCl
and 2 mM CaCl2 (Richter et al, 2004). A
blank determination of basal assay mix-
ture without plasma was performed to
observe the spontaneous hydrolysis of
paraoxon and diazoxon solutions (Senti et
al, 2001). One milliter of substrate solution
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was placed in a cuvette. Upon addition of
the neat plasma sample (10 µ l for
paraoxonase and 5 µl for diazoxonase) to
the substrate solution, the reaction was
monitored for 2 minutes at 25ºC in a UV-
Vis spectrophotometer (Varian Cary 50,
USA). Measurement of activity was per-
formed using the “Kinetics” application.
Paraoxonase and diazoxonase activities
were expressed as 1 µmol of substrate hy-
drolyzed per minute per liter of plasma.
The extinction coefficients for p-
nitrophenol (hydrolysis product for
paraoxon) and 2-Isopropyl-4-methyl-6-
hydroxypyrimidine (for diazoxon) were 18
and 3 mM-1cm-1 at pH 8.5, respectively. A
two-dimensional plot of initial rates of
diazoxon hydrolysis on the y axis versus
rates of paraoxon hydrolysis on the x axis
was used for the simultaneous determina-
tion of paraoxonase and diazoxonase ac-
tivity genotyping in addition to
phenotyping.
Statistical analysis
Univariate analysis was performed for
predictors of continuous variables, ie
PON1 activity. Two models were con-
structed for the prediction of PON1 activ-
ity. The general linear model procedure
was used to evaluate the factors and
covariates that were significant predictors
of PON1 activity in the study groups. The
variables included in Model 1 were PON1
polymorphisms PON1192QR and PON155LM,
ethnicity, alcohol status, smoking status,
age, systolic blood pressure (SBP), diastolic
blood pressure (DBP), fasting blood glu-
cose, glycated hemoglobin (HbA1c), body
mass index (BMI), HDL-C, LDL-C, total
cholesterol (TC), and triglyceride (TG) lev-
els based on studies by Rahmani et al
(2002), Hofer et al (2006) and Parra et al
(2006). Variations in these two PON1 poly-
morphisms with the same samples have
been reported previously (Poh et al, 2007).
The variables in Model 2 were those that
were used in Model 1 but excluded the two
PON1 polymorphisms. The final variables
that showed significant values taken to-
gether with the means, pairwise compari-
sons and Bonferroni post hoc (categorical
variables) and parameter estimates (con-
tinuous variables) were determined to be
predictors of PON1 activity. A large regres-
sion coefficient, as denoted by B, means a
particular risk factor strongly influenced
the probability of the outcome in question.
A near-zero regression coefficient means
the risk factor had little influence on the
probability of that outcome.
A multivariate analysis of variance
(MANOVA) was performed on predictors
of two continuous dependent variables
which are PON1 activities towards
paraoxon and diazoxon. The tests exam-
ined for differences in the dependent vari-
ables POase and DZOase activities simul-
taneously.
Multinomial regression was per-
formed for prediction analyses in categori-
cal outcomes (test groups). Two multino-
mial logistic regression models were fit-
ted to evaluate risk factors in association
with complications in type 2 DM based on
a study by Sarkar et al (2006). The variables
included in Model 1 were ethnicity, dia-
betic status, smoking status, alcohol sta-
tus, age, BMI, and DZOase and POase ac-
tivities. The variables included in Model
2 were the PON1 polymorphisms
(PON1192QR and PON155LM) ethnicity, dia-
betic status, smoking status, alcohol con-
sumption status, age, BMI, and DZOase
and POase activities, to observe whether
PON1 polymorphisms improved the pre-
dictive value of PON1 activity in the study
groups. If the resultant model-fitting-in-
formation was significant, then the
stepwise method using the forward-entry
procedure was performed. The final vari-
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samples t test was performed (p=0.749).
PON1 activity towards diazoxon was
higher (p=0.008) in females (10,061 ± 5,102
U/l) than in males (8,527 ± 5,060). When
the rate of hydrolysis of diazoxon versus
paraoxon was plotted, the population fell
into three groups (Fig 1): individuals func-
tionally homozygous for PON1192Q (QQ),
heterozygotes (PON1Q/R192Q/R; QR) and in-
dividuals homozygous for PON1192R (RR).
When PON1 activities towards para-
oxon and diazoxon were demarcated by
tertiles to classify as being low, intermedi-
ate or high, the thresholds for the first and
second tertiles were at 368 and 622 U/l for
overall PON1 activity towards paraoxon,
and 6,690 and 10,640 U/l for PON1 acti-
vity towards diazoxon, respectively.
When PON1 activities towards paraoxon
and diazoxon were demarcated by tertiles
within the genotypes of the PON1192 poly-
Fig 1–Plot of PON1192 bivariate phenotype versus genotype in
the determination of the functional genomics of plasma
PON1. The plot gave rise to three sub-populations repre-
senting three genotypes as indicated by the three colors.
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ables that showed significant values based
on the likelihood-ratio-tests and Wald sta-
tistic, taken together with odds ratio
Exp(B) and 95% confidence interval for
categorical variables and parameter esti-
mates for continuous variables, were de-
termined to be predictors of CVD compli-
cation in type 2 DM.
Analysis was performed using SPSS
13.0 for Windows statistical software. A
p-value of <0.05 was taken to be statisti-
cally significant.
RESULTS
Demographic characteristics of the sample
population
The sample population consisted of
199 females and 129 males. The mean age
was 52. ± 10.9 years old. The distribution
of the sample population according to
study groups was as fol-
lows: Group 1 (control) –
46.6%, Group 2 (diabetics) –
13.4%, Group 3 (CVD) –
10.7%, and Group 4 (dia-
betic and CVD) – 29.3%.
When Groups 1 and 3 were
combined, the total was
57.3% for non-diabetics, and
42.7% for diabetics (Groups
2 and 4).
Status of PON1
The rates of spontane-
ous hydrolysis for paraoxon
and phenylacetate were less
than 0.0001% for a typical
sample of plasma.
There was no signifi-
cant difference in PON1 ac-
tivity between paraoxon in
males (541 ± 271 U/l) and in
females (552 ±  327 U/l)
when the independent
PON1 ACTIVITY IN TYPE 2 DIABETES
Vol  41  No. 5  September  2010 5
Ethnicity POase activitya, U/l DZOase activityb, U/l
Malay 592 ± 308 10238 ± 5806
Chinese 583 ± 289 8404 ± 4479
Indian 457 ± 295 9371 ± 4458
Total 540 ± 304 9459 ± 5054
Table 1
Effect of ethnicity on PON1 activity towards paraoxon and diazoxon.
Values are mean ± SD. Equal variances were assumed. One-way ANOVA, ap<0.001, bp=0.029. Tukey’s
post hoc test was used.
Study group POase activitya, U/l DZOase activityb, U/l
Group 1 581 ± 315 10006 ± 4692
Group 2 583 ± 342 8679 ± 3666
Group 3 647 ± 307 11000 ± 6100
Group 4 442 ± 244 8378 ± 5766
Total 548 ± 306 9458 ± 5133
Table 2
PON1 activity towards paraoxon and diazoxon by study group.
Values are mean ± SD. Equal variances were assumed. One-way ANOVA, ap<0.001, bp=0.017. Tukey’s
post hoc test was used.
morphism, the thresholds were 184 and
261 U/l for the QQ genotype, 431 and 573
for the QR genotype, and 640 and 913 U/l
for the RR genotype, respectively.
Relationship of ethnicity to PON1 activity
PON1 activity towards both sub-
strates differed significantly by ethnicity
(Table 1). Malays and Chinese had signifi-
cantly higher PON1 activity towards
paraoxon than Indians (ANOVA, p<0.01),
and Malays had higher PON1 activity to-
wards diazoxon than Chinese subjects
(p=0.022).
Association of PON1 activity with dia-
betic status
The difference in PON1 activity to-
wards the two substrates by diabetic sta-
tus was significant (Table 2). The post hoc
test showed Groups 1-3 had similar PON1
activity toward paraoxon, which was
higher than Group 4. There was no
pairwise difference in PON1 activity to-
wards diazoxon between Group 1 and the
other groups. There was also no difference
between Group 2 and the other groups.
However, Group 3 had higher PON1 ac-
tivity towards diazoxon tan Group 4
(p=0.046).
When the univariate analysis was per-
formed, ethnicity, PON155LM and -192QR
polymorphisms, age, and TG, TC, HDL-C
and LDL-C levels were significant predic-
tors of PON1 activity towards paraoxon.
Diabetic status and HDL-C level were not
significant predictors (p=0.1) in Model 1
(test results not shown). Model 2, which
did not include the two PON1 polymor-
phisms, showed ethnicity, diabetic status
and HDL-C level were significant predic-
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Variable Subgroup B SE t p-value Observed
powera
Intercept 238.637 54.507 4.378 0.000 0.992
Ethnicity Malay 100.035 37.602 2.660 0.008 0.756
Chinese 95.420 43.208 2.208 0.028 0.596
Indian 0b
Study group Control 84.231 42.338 1.990 0.047 0.509
DM 123.323 53.838 2.291 0.023 0.627
CVD 132.744 60.643 2.189 0.029 0.588
DM and CVD 0b
HDL-C - 147.378 47.943 3.074 0.002 0.865
Table 3b
Parameter estimates for prediction of PON1 activity (Model 2).
General linear model was used. Dependent variable: POase activity. aComputed using α=0.05.
bThis parameter is set to zero because it is the reference category.
Source F p-value Observed
powera
Ethnicity 4.111 0.017 0.726
Diabetic status 2.601 0.052 0.636
HDL-C 9.450 0.002 0.865
Table 3a
Tests of between-subjects effects for
prediction of PON1 activity (Model 2).
Dependent variable: POase activity;
aComputed using α=0.05.
tors of PON1 activity (Tables 3a, b). This
suggests the PON1 polymorphisms were
confounding factors in Model 1.
Model 2 predicts Malays and Chinese
would have higher PON1 activity towards
paraoxon than Indians. The three groups
comprised of control subjects, and those
with DM and CVD (Groups 1-3) were pre-
dicted to have higher PON1 activity com-
pared to those with DM having complica-
tions (Group 4). The model also indicated
that higher HDL-C level predicted higher
PON1 activity. In summary, the prediction
of PON1 activity in Model 2 is governed
by the following equation:
PON1 activity = 239 + 100 (Malay)
+ 95 (Chinese) + 84 (Control)
+ 123 (DM) + 133 (CVD)
+ 147 (HDL)
Tables 4a and b show the model pre-
dicts activity against diazoxon. Age, TG,
TC and LDL levels were significant pre-
dictors of activity against diazoxon
(p=0.05), while ethnicity and CVD status
were not significant (p=0.1). Based on this
model, Chinese are predicted to have
lower DZOase activity than Indians. DZO
activity was predicted to decrease with
age, TG and LDL levels, and increase with
higher TC levels. CVD status does not ap-
pear to predict DZOase activity.
When multivariate analysis was per-
formed, ethnicity and diabetic status were
significant predictors of POase activity,
while ethnicity, smoking status, age, TG,
TC and LDL-C levels were significant pre-
dictors of DZOase activity (Tables 5a, b).
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Based on this multivariate analysis, Chi-
nese and Malays were predicted to have
higher POase activity than Indians. POase
activity was also predicted to be higher in
type 2 diabetics without CVD than diabe-
tics with CVD complications. Chinese
were predicted to have lower DZOase ac-
tivity than Indians. Control subjects had
lower DZOase activity than diabetics with
complications. Non-smokers were pre-
dicted to have higher activity than smok-
ers. DZOase activity was predicted to de-
crease with age, TG and LDL levels, and
increase with higher TC levels.
Hence, both univariate and multivari-
ate analyses appeared to concur regarding
predictors of activity towards paraoxon
and diazoxon.
Predictors of complications in type 2 DM
Based on Model 1, the model-fitting-
information indicates the presence of sig-
nificant predictors, which were shown by
the likelihood-ratio-test to be age, BMI and
Source F p-value Observed powera
Ethnic 2.621 0.074 0.520
Age 8.677 0.003 0.836
TG 14.964 0.000 0.971
Total chololeoterol 15.812 0.000 0.977
LDL 11.908 0.001 0.931
CVDstat 2.523 0.082 0.504
General linear model was used. Dependent variable: DZOase activity. aComputed using α=0.05.
bThis parameter is set to zero because it is the reference category. Non-HT included diabetics and
non-diabetic controls who did not have HT).
Parameter B SE t p-value B
Intercept 9,022.387 2,271.115 3.973 0.000 0.977
Malay 35.027 640.959 0.055 0.956 0.050
Chinese -1,466.563 722.549 -2.030 0.043 0.525
Indian 0(b)
Age -83.895 28.480 -2.946 0.003 0.836
TG -1,312.597 339.323 -3.868 0.000 0.971
Total choloeoterol 3,383.169 850.810 3.976 0.000 0.977
LDL -3,212.277 930.862 -3.451 0.001 0.931
Hypertensive 1,313.215 918.068 1.430 0.154 0.297
Non-HT -78.083 928.424 -0.084 0.933 0.051
CVD and HT 0(b)
Dependent variable: DZOase activity. aComputed using α=0.05.
Table 4a
Tests of between-subject effects for prediction of DZOase activity.
Table 4b
Parameter estimates in prediction of DZOase activity.
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Source Dependent variable F p-value Observed powera
Ethnicity POase activity 3.079 0.047 0.591
DZOase activity 3.494 0.032 0.650
Diabetic status POase activity 1.505 0.213 0.396
DZOase activity 1.683 0.171 0.439
Smoking status POase activity 0.413 0.521 0.098
DZOase activity 3.296 0.070 0.440
Age POase activity 0.013 0.911 0.051
DZOase activity 10.201 0.002 0.890
TG POase activity 0.542 0.462 0.114
DZOase activity 2.965 0.086 0.404
TC POase activity 0.500 0.480 0.109
DZOase activity 5.244 0.023 0.627
LDL POase activity 0.209 0.648 0.074
DZOase activity 4.582 0.033 0.569
Table 5a
Tests of between-subject effects on multivariate analysis.
a Computed using α=0.05.
PON1 activity towards paraoxon, in that
order (p<0.001). Parameter estimates in
this model indicate the older the person
is, the higher the likelihood he will have
DM, followed by DM and CVD (Tables
6a,b). Similarly, the higher the BMI, the
higher the likelihood he will present with
DM, then CVD, followed by DM and CVD.
On the other hand, the lower the PON1
activity towards paraoxon, the higher the
likelihood the person will present with
CVD, DM and DM with CVD, in order of
descending likelihood.
In Model 2, the addition of PON1
polymorphisms as variables factors did
not improve the predictive value of PON1
activity toward paraoxon, since the para-
meters of the B coefficients, Wald statis-
tics and p-values after regression analysis
remained identical to those in Model 1.
Summary of predictors
Based on univariate (Model 2) and
multivariate analyses, ethnicity, diabetic
status and HDL-C level had an impact on
PON1 activity toward paraoxon. Based on
Model 1 from logistic regression analysis,
age, BMI and PON1 activity toward
paraoxon had an impact on the study
groups. Among the variables, diabetic sta-
tus and PON1 activity toward paraoxon
were mutually present as a significant pre-
dictor of the other. This is consistent with
the initial ANOVA that showed there was
a significant difference in PON1 activity
toward paraoxon among the four study
groups.
DISCUSSION
Spontaneous hydrolysis of paraoxon
and diazoxon did not affect PON1 acti-
vity in this study. Therefore, assays of
PON1 activity were not corrected for spon-
taneous hydrolysis. Eckerson et al (1983)
showed spontaneous, or nonenzymatic,
hydrolysis is not significant except in
samples having extremely low activity.
PON1 ACTIVITY IN TYPE 2 DIABETES
Vol  41  No. 5  September  2010 9
Dependent Parameter B SE t p-value Observed
variable powera
POase activity Intercept 127.701 270.729 0.472 0.637 0.076
Malay 85.506 40.844 2.093 0.037 0.551
Chinese 95.305 45.163 2.110 0.036 0.557
Indian 0b
Control 60.605 63.636 0.952 0.342 0.158
DM 115.271 57.244 2.014 0.045 0.519
CVD 91.256 73.881 1.235 0.218 0.234
DM & CVD 0 b
Non-smoker -54.170 84.295 -0.643 0.521 0.098
Smoker 0 b
Age .211 1.880 0.112 0.911 0.051
TG -23.188 31.509 -0.736 0.462 0.114
Totalchol 55.500 78.522 0.707 0.480 0.109
LDL -36.298 79.476 -0.457 0.648 0.074
DZOase activity Intercept 12,223.792 4,492.346 2.721 0.007 0.774
Malay 223.859 677.744 0.330 0.741 0.063
Chinese -1,662.132 749.420 2.218 0.027 0.599
Indian 0 b
Control -1,792.341 1,055.950 1.697 0.091 0.395
DM -1,053.248 949.884 1.109 0.268 0.197
CVD 30.402 1,225.948 0.025 0.980 0.050
DM & CVD 0 b
Non-smoker 2,539.283 1,398.746 1.815 0.070 0.440
Smoker 0 b
Age -99.635 31.196 3.194 0.002 0.890
TG -900.372 522.846 1.722 0.086 0.404
Totalchol 2,983.791 1,302.954 2.290 0.023 0.627
LDL -2,822.800 1,318.787 2.140 0.033 0.569
Table 5b
Parameter estimates on multivariate analysis.
General linear model used. Dependent variables: POase and DZOase activities. aComputed using
α=0.05. bThis parameter is set to zero because it is the reference category.
In the present study, diabetics with
complications were found to have signifi-
cantly lower PON1 activity than diabetics
without complications. PON1 activity was
also found to be lower in diabetics with
CVD than those without CAD (Tsuzura
et al, 2004; Kosaka et al, 2005; Inoue et al,
2006; Lakshman et al, 2006; Moldoveanu
et al, 2006). Investigations of diabetic com-
plications in relation to PON1 activity have
also been carried out, suggesting the role
of PON1 in the attenuation of premature
atherosclerosis in diabetes (Mackness et al,
2002). The percentage of patients with
lower HDL-C was higher in diabetic pa-
tients with CVD than in diabetics without
CVD or healthy subjects (Moldoveanu et
al, 2006).
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The reduced activity of PON1 and re-
duced HDL levels in diabetics with CVD
may be due to the increased glycation of
HDL. Glycation of HDL increases its turn-
over and reduces its efficiency during cho-
lesterol transport (Hedrick et al, 2000). The
effect of glucose in vitro on PON1 lactonase
activity and HDL was studied by
Rosenblat et al (2007). Sera from healthy
subjects were incubated with glucose in
increasing concentrations. This resulted in
a significant glucose dose-dependent re-
duction in PON1 activity in both the se-
rum and HDL fraction. The ability of HDL
to induce macrophage cholesterol efflux
was reduced. Western blot analysis dem-
onstrated glucose caused the dissociation
of PON1 from HDL to a free PON1 form
in a glucose dose-dependent manner.
PON1 lactonase activity was 60% lower in
Effect
-2 Log likelihood of Chi-square df p-value
reduced model
Intercept 762.183 79.119 3 0.000
Age 772.538 89.475 3 0.000
BMI 708.853 25.790 3 0.000
PON 697.540 14.476 3 0.002
Diabetic statusa B SE Wald df p-value Exp(B)
Lower Upper
bound bound
DM Intercept -8.164 1.799 20.588 1 0.000
Age 0.078 0.019 16.225 1 0.000 1.081 1.041 1.123
BMI 0.111 0.043 6.561 1 0.010 1.118 1.026 1.217
PON1 0.000 0.001 0.005 1 0.942 1.000 0.999 1.001
CVD Intercept -8.929 1.974 20.461 1 0.000
Age 0.067 0.021 9.878 1 0.002 1.070 1.026 1.116
BMI 0.138 0.046 8.993 1 0.003 1.147 1.049 1.255
PON1 0.001 0.001 1.231 1 0.267 1.001 0.999 1.002
DM & CVD Intercept 11.872 1.730 47.073 1 0.000
Age 0.142 0.018 61.197 1 0.000 1.152 1.112 1.194
BMI 0.175 0.040 19.363 1 0.000 1.192 1.102 1.288
The Chi-square statistic is the difference in -2 log-likelihoods between the final model and reduced
model. The reduced model is formed by omitting an effect from the final model.
Table 6a
Likelihood ratio tests on logistic regression analysis.
Model fitting criteria Likelihood ratio tests
Table 6b
Parameter estimates for logistic regression analysis.
Multinomial logistic regression model was used. aThe reference category is Control.
95% Confidence
interval for Exp (B)
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Subject population Sample POase DZOase Reference
activity (U/l)a activity (U/l)b
Healthy Sera 140 ± 43 - - Eckerson et al, 1983
1,008±244c
Healthy Sera 144 (129-160)d-Geneva - Blatter-Garin et al, 1994
142 (122-164)d-Manchester
Healthy Sera 142 (72-283)d - Abbott et al, 1995
Healthy Sera 215 (26-621)d - Mackness et al, 1998
DM 164 (8-467)d
Healthy Sera 181±134 - James et al, 1998
Healthy Sera 44d; 82c - Sozmen et al, 1999
Type 2 DM 44d; 91c
Type 2 DM with HPT 35d; 74c
Healthy Sera 162 4,323 Inoue et al, 2000
Healthy control Plasma 685c 10,009
Vascular disease 546c 8,493 Jarvik et al, 2000
Diabetic retinopathy Sera 113 (3-415)d - Mackness et al, 2000a
Healthy Sera 226c - Senti et al, 2001
CAD diabetics and non-diabetics Sera 81d - Rahmani et al, 2002
Healthy Sera 286c 6.5 Yamada et al, 2001
Healthy Sera 688 ± 412c; - Ferre et al, 2002
412 ± 153d
Healthy Sera - 14.17 Cherry et al, 2002
DM Sera 238 ± 80 - Tsuzura et al, 2004
DM with CVD 259 ± 93
Familial hypercholesterolemia Sera 732 (2 M NaCl) 6,648 van Himbergen et al,
2005
Healthy Sera 340 ± 37d - Rosenblat et al, 2005
DM 183 ± 35d
Hypercholesterolemia 208 ± 12d
Peripheral arterial disease Sera 294d - Pasqualini et al, 2005
DM Sera 331 ± 29c - van Wijk et al, 2006
Healthy control Sera 300 - Lakshman et al, 2006
DM without CVD 200
DM with CVD 200
Healthy control Sera 269d - Mastorikou et al, 2006
DM 114d
CHD 151d
Healthy adults Plasma 1,024c - Holland et al, 2006
Healthy newborns 315c -
Healthy control Sera 413c Juretic et al, 2006
DM 464c
Healthy control Sera 60 ± 27d - Hashim and Zarina,
DM 21 ± 3d 2007
Table 7
Comparison of POase and DZOase activity in human subjects.
aUnits in nmol/min/l. bUnits in µmol/min/l. cWith 1 M NaCl. dWithout NaCl.
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diabetics than in healthy subjects. Free
PON1 and HDL-bound PON1 inactivation
rates were higher in diabetics than in
healthy subjects. The authors concluded
the inactivation and dissociation of PON1
from HDL by high glucose concentrations
may step up the atherosclerotic process in
diabetic patients.
In this study, healthy subjects, diabet-
ics and CVD patients had similar activity
towards paraoxon, and this was higher
than PON1 activity in diabetics with com-
plications. Hashim and Zarina (2007) re-
ported similar results. Mastorikou et al
(2006) showed PON1 activity in healthy
subjects was higher than in diabetics,
while diabetics had lower activity than
CHD patients. The present study also
showed comparable activity towards
paraoxon between diabetics without com-
plications and healthy subjects. Rahmani
et al (2002) showed there was no signifi-
cant difference in activity towards
paraoxon in their study groups, which
consisted of coronary artery disease (CAD)
patients with diabetes, CAD patients with-
out diabetes, and healthy subjects matched
for age and sex. In some instances, PON1
activity was higher in diabetics than
healthy subjects.  Juretic et al (2006) found
PON1 activity was slightly higher in dia-
betics, which they associated with higher
cholesterol levels. They also found the
PON1192R allele was present more com-
monly in diabetics. Since hydrolysis of
paraoxon by this allele is more efficient
than the PON1192Q allele, this may have
contributed to the higher PON1 activity
measured. A study on variation in PON1
polymorphism showed a higher frequency
of the PON1192R allele in the general popu-
lation (Poh and Maniandy, 2007). In a
study by Lakshman et al (2006), diabetic
patients who had undergone coronary ar-
tery bypass surgery were more aggres-
sively treated than were DM-CVD and
DM+CVD groups, receiving a higher
mean dose of statins which might have
contributed to the additional antioxidant
potential as translated by the associated
activity of PON1. The authors demon-
strated a negative correlation for both se-
rum paraoxonase (POase) and homocys-
teine thiolactonase (HTLase) activity with
the degree of CVD. There was a 30% de-
crease in POase activity in diabetic patients
without overt CVD compared to healthy
subjects. Similarly, HTLase activity in dia-
betics without overt CVD was 11% lower
than healthy subjects. Increased
angiographic atherosclerotic activity, as
indicated by the Gensini Score, was asso-
ciated with decreased PON1 activity. The
authors attributed the lower PON1 activ-
ity to diabetic pathophysiology rather than
PON1 polymorphism, since there was no
difference in the distribution of genotypes
between the groups. They also found the
protective role of HDL against LDL oxi-
dation was negatively correlated with the
degree of CVD. The shorter lag time of
LDL oxidation kinetics in diabetics with
CVD compared to diabetics without CVD,
could be due to lower PON1 activity; this
suggests combined accelerated atherogen-
esis with diabetic pathology.  Table 7 com-
pares the relationship between disease sta-
tus and PON1 activity towards paraoxon
and diazoxon. Variation in PON1 activity
may have been due to several factors, such
as variation in the salt introduced into the
activity assay buffer, whether sera or
plasma was used and the pH of the buffer.
The present study also showed that
CVD patients had higher PON1 activity
towards diazoxon than diabetics with
complications across the PON1192 geno-
types. When stratified, activity towards
diazoxon was higher in healthy subjects
and diabetics without complications than
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diabetics with complications for PON1192RR
subjects. Studies of activity towards
diazoxon in relation to diabetic complica-
tions are currently lacking. Yamada et al
(2001) reported that there was a positive
association between insulin resistance and
activity towards diazoxon in the non-dia-
betic population. Their results suggest
hyperinsulinemia is a factor contributing
to variability in PON1 activity. However,
there was no association noted between
common carotid artery intima-media
thickness (a measure of early atheroscle-
rosis) and activity towards diazoxon (van
Himbergen et al, 2005).
However, some studies have shown
no discrimination in PON1 activity when
diabetics were compared with normal sub-
jects. Hofer et al (2006) found no signifi-
cant associations between PON1 activities
and diabetes complications. In a study of
diabetics in a Croatian population, PON1
activity towards paraoxon and pheny-
lacetate was measured (Juretic et al, 2006).
The authors found that total cholesterol
and LDL-cholesterol in female diabetics
and triglyceride concentration in male dia-
betics were higher than in normal subjects.
PON1 activity, however, was similar be-
tween diabetics and normal subjects.
In the present study, the results of
stepwise multinomial regression analysis
confirmed that age, BMI and PON1 activ-
ity towards paraoxon were associated with
complications in type 2 diabetes. The re-
sults of univariate analysis showed that
ethnicity, diabetic status and HDL-C level
had an impact on PON1 activity. Thus dia-
betic status and PON1 activity were mu-
tually present as significant predictors,
independent of PON1 polymorphisms.
These findings are in agreement with those
of Tsuzura et al (2004), where diabetics
with complications had lower PON1 ac-
tivity than diabetics without complica-
tions. These observations support the hy-
pothesis that PON1 prevents LDL lipid
peroxidation, thus protecting against dia-
betic complications (Lakshman et al, 2006).
The attenuation of PON1 activity could
result in higher susceptibility to LDL oxi-
dation, especially in diabetics suffering
oxidative stress (Tsuzura et al, 2004). How-
ever, the direct effect of PON1 on diabetes
development has not been fully studied
(Rozenberg et al, 2008). HDL-C was a sig-
nificant contributor to the variation in
PON1 activity towards paraoxon. These
findings are consistent with those of
Phuntuwate et al (2005). Furthermore, the
association between PON1 activity and
clinical events was observed in a follow-
up study spanning 9 years (Inoue et al,
2006). It was found that PON1 activity re-
tained a significant inverse association
with CVD, whereby an increased inci-
dence of CVD was detected in diabetic
patients with low PON1 levels. A low
PON1 concentration may be a useful pre-
dictor of CVD in diabetic patients.
This is the first evaluation of para-
oxonase and diazoxonase activities in
three major Malaysian ethnic groups. We
found that diabetics with CVD complica-
tions had lower PON1 activity against
paraoxon than diabetics without such
complications. Monitoring PON1 activity
as a parameter of vascular risk could im-
prove the prognosis of complex vascular
disease in type 2 diabetes.
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